Bone and body composition analyzed by Dual-energy X-ray Absorptiometry (DXA) in clinical and nutritional evaluation of young patients with Cystic Fibrosis: a cross-sectional study by Lucidi, Vincenzina et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Bone and body composition analyzed by Dual-energy X-ray 
Absorptiometry (DXA) in clinical and nutritional evaluation of 
young patients with Cystic Fibrosis: a cross-sectional study
Vincenzina Lucidi*1, Carla Bizzarri2, Federico Alghisi1, Sergio Bella1, 
Beatrice Russo1, Graziamaria Ubertini2 and Marco Cappa2
Address: 1Unit of Cystic Fibrosis, Department of Pediatric Medicine - Bambino Gesù Children's Hospital, IRCCS, Rome, Italy and 2Unit of 
Endocrinology, Department of Pediatric Medicine - Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
Email: Vincenzina Lucidi* - lucidi@opbg.net; Carla Bizzarri - bizzarri@opbg.net; Federico Alghisi - federicoalghisi@hotmail.com; 
Sergio Bella - bella@opbg.net; Beatrice Russo - beatricebr@libero.it; Graziamaria Ubertini - ubertini@opbg.net; Marco Cappa - cappa@opbg.net
* Corresponding author    
Abstract
Background: the improved general therapy has led to reduced morbidity and mortality from
Cystic Fibrosis (CF), and bone status may have a potentially greater clinical impact.
We investigated the correlation between the severity of the clinical condition, bone status and
body composition parameters, in a group of children and young adults with CF.
Methods: we measured lumbar spine bone density and total body composition by dual energy x-
ray absorptiometry (DXA) in 82 consecutive CF patients (42 males; median age: 13 years - range:
5-30). Eighty-two healthy subjects, matched for age, gender, height and pubertal stage were
recruited as a control group.
Results: 37 patients (45.1%) had a normal bone mineral density (BMD). A BMD reduction were
observed in 45 (54.8%) patients. Lumbar spine Z score was positively related to Body Mass Index
(BMI) and a higher Shwachman-Kulczycki score, and negatively related to Crispin-Norman score.
A positive and significant correlation was also observed between lumbar spine Z score and total
body composition.
Conclusion: a significant BMD reduction can be present early in CF children and adolescents. A
careful follow up of bone status is required starting in childhood.
Background
With the dramatic improvement in life expectancy for
cystic fibrosis (CF) patients over the past 25 years, atten-
tion has turned towards the complications of this disease.
In particular, research has been directed towards factors
which may maximize both survival and quality of life in
the longer term [1,2]. Osteopenia, which is commonly
found in adult CF patients exacts a considerable toll
through fragility fractures; back pain and kyphosis can
cause a further deterioration in respiratory status [3-5].
Many reasons have been suggested for the observed reduc-
tion in bone mineral density (BMD): small bone size,
poor nutritional intake, pancreatic insufficiency, calcium
and vitamin D malabsorption, reduced levels of physical
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activity, corticosteroid usage, pubertal delay, chronic res-
piratory infection and elevated levels of osteoclast activat-
ing cytokines [6]. Failure to accrete a bone mass at an
appropriate rate, rather than bone loss, has been hypoth-
esized to play the major role [7].
Until the late 1990s, over 30% of CF subjects were
reported to have a very low BMD, with lower values in
men than in women [8]. The reduction in BMD seems to
evolve during adolescence, and becomes more evident in
adulthood. More recently, some studies [9,10] have
reported overall normal BMD in well-nourished CF sub-
jects. A few authors have described that ΔF508 mutation
in the homo- or heterozygous state could represent an
independent risk factor for reduced bone density in CF
[11].
The purpose of this study was to analyze BMD and body
composition by DXA in a large heterogeneous group of
children and young adults with CF.
We investigated the correlation between various indica-
tors of clinical condition (especially nutrition and lung
function) and bone status.
Methods
Subjects
The study was a cross-sectional, observational evaluation
of children and young adults with CF. All the patients,
aged between 5 and 30 years, attending the Cystic Fibrosis
Unit at the Bambino Gesù Children's Hospital of Rome,
were invited to participate in the study, without obliga-
tion and without specific selection criteria. The study
period extended from July 2007 to July 2008. Eighty-two
(42 males, 40 females) consecutive patients underwent
the evaluation described below. Median age was 13 years
(range 5-30). Twenty-seven patients (32.9%) were chil-
dren (aged 5 years to puberty), 45 (54.9%) were adoles-
cents (from the onset of puberty to 18 years), and 10
(12.2%) were young adults (older than 18 years). The
diagnosis of CF had been confirmed by the sweat test and
by CF gene mutation analysis in all patients. All patients
were on unrestricted high caloric diet (120% of the daily
caloric intake), in accordance with standard recommen-
dations for CF care. No patient used supplemental noctur-
nal enteral feeding. All patients took an oral multivitamin
preparation, including 400 UI/day of vitamin D; no oral
calcium supplement was used. In our Unit, oral glucocor-
ticoids are used only in cases of allergic bronchopulmo-
nary aspergillosis (ABPA), severe asthma, and in seriously
ill patients. During the previous 2 years, no patient had
been treated with oral steroids for more than 15 days. All
patients were receiving inhaled steroids; cumulative dose
was calculated in mg as the product of mean daily dose ×
365 × duration in years. Medical history for bone fractures
was negative in all patients. All subjects underwent plain
chest X-rays (lateral projection) to exclude unknown ver-
tebral fractures. No patient was taking bone sparing drugs.
Clinical and genetic features of CF subjects are summa-
rized in Table 1.
The areal BMD (g/cm2) measured by DXA is particularly
misleading when measured in growing patients, as it
underestimates the true density value for smaller bones
and overestimates it for larger bones [12]. Furthermore, it
is well known that patients with CF might present growth
retardation and pubertal delay, and consequently skeletal
size and mineralization may be decreased. In order to
minimize the influence of bone size on DXA measured
bone mineral content (BMC) and BMD, we intentionally
recruited 82 control subjects (42 males) matched for age,
gender, pubertal stage and height. For every patient we
selected one control subject, matching criteria were: age ±
12 months, height ± 10 cm, and the same pubertal stage.
Control subjects were recruited from amongst the healthy
children attending the outpatient clinic of our Hospital.
Young adult control subjects were students or members of
the staff. The study was approved by the Bambino Gesù
Table 1: Clinical and genetic features of CF group
Number (%) males females
Homozygous for ΔF508 mutation 16 (19.5) 9 7
Heterozygous for ΔF508 mutation 39 (47.6) 22 17
No allele for ΔF508 mutation 27 (32.9) 12 15
Pancreatic insufficiency 80 (97.6) 38 42
CF-Related Diabetes 14 (17.1) 6 8
CF-Related Liver Disease* 11 (13.4) 6 5
*:According to Colombo et al [35]BMC Pediatrics 2009, 9:61 http://www.biomedcentral.com/1471-2431/9/61
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Institutional Research Committee and written informed
consent was obtained prior to participation from patients
and/or parents.
Methods
Weight was assessed by a digital scale, height by a
Harpenden stadiometer. Body mass index (BMI) was cal-
culated from the ratio of weight/height2 (kg/m2). Due to
the presence of pediatric subjects, BMI was also expressed
as BMI-Z score, using the Italian reference data [13].
Pubertal status was determined using breast and pubic
hair stages in girls, testicular and pubic hair stages in boys,
according to the Tanner criteria [14]. Bone status and
body composition were analyzed by DXA (DXA Hologic
QDR, Waltham, Mass.) equipped with standard density
software. Total body fat mass (excluding head) and lean
mass were analyzed by DXA and expressed in grams. BMD
(g/cm2) was assessed at the lumbar spine (L1-L4); the
results were expressed as Z score for age, sex and ethnicity
according to the reference data given by the Hologic soft-
ware. Z scores were calculated by subtracting the sex- and
age-specific population mean BMD from the CF subject's
BMD; this value was then divided by the SD of the sex-
and age-specific mean. The areal BMD measurements do
not take into account that the actual bone volume is
strictly related to body size, a particularly important
aspect when evaluating a growing skeleton. A reduced
BMD can be the result of a real reduction in BMD and/or
the result of a small bone size [12]. To reduce these dis-
crepancies, we also calculated lumbar spine bone mineral
apparent density (BMAD), by dividing the vertebral BMC
(expressed in grams) by the estimated volume, assuming
that vertebral bodies are cubical [15]. The BMAD repre-
sents the estimated cortical and trabecular volumetric (g/
cm3) bone density within the estimated envelope of the
vertebral body.
The definition criteria of osteoporosis in pediatric age is
not completely established, due to the lack of the linear
correlation, seen in adults, between the severity of bone
demineralization and the risk of fractures. Even if our
study population also comprises a few young adult sub-
jects, we arbitrarily used the standards recently proposed
for pediatric subjects to define bone density reduction
[12]. We considered normal BMD a lumbar spine Z score
>-1, mild BMD reduction a lumbar spine Z score lower
than -1.0 but higher than -2, severe BMD reduction a
lumbar spine Z score lower than -2.0. Pulmonary function
was assessed by forced expiratory volume in one second
and expressed as percentage of expected for height
(FEV%). Disease severity was globally evaluated by the
Shwachman-Kulczycki score, in which four separate
aspects are assessed: activity, physical examination, nutri-
tion and chest roentgenogram. Each category was given an
equal value of 25 points, each item being rated on a 5-
point scale, giving a total score of 100 points, where a
higher score indicated better health [16]. Crispin-Norman
radiological scoring system was used to evaluate the
degree of lung damage. It describes radiological lung
lesions: air trapping, linear markings, nodular-cystic
lesions, large lesions, general severity, attributing from 1
to 4 or 5 points to describe the increasing severity. Higher
scores are associated with increased severity with a total of
25 demerit points [17].
Statistical analysis
The statistical analyses were performed using the SPSS
software, version 6.1 for Windows (SPSS Inc., Chicago,
Illinois, USA). The symmetrically distributed data are
expressed as mean ± 1SD. Those variables that showed
evidence of being asymmetric are presented as median.
Linear regression analysis was used to study the relation
between lumbar spine Z score and body composition
parameters, and to analyze the correlation between bone
status and the indexes of disease severity. T-test and One-
way Anova were used to calculate differences between
means. The Mann-Whitney test was used to compare
notably asymmetric variables. P < 0.05 was considered
statistically significant.
Results
Mean FEV1% predicted in our population was 84.7 ±
20.5%, four patients (4.8%) had a severe lung disease
with a FEV1% < 40%. Mean Shwachman-Kulczycki score
was 87.64 ± 14.07, mean Crispin-Norman score was 8.32
± 4.5. Mean cumulative dosage of inhaled steroids was
721 mg ± 185. Mean lumbar spine BMD Z score and mean
lumbar spine BMAD were significantly different in CF
subjects and control group; auxological characteristics
and bone status of the two groups are shown in Table 2.
Thirty-seven subjects had a normal BMD, with a Z score
higher than -1 (45.1% - 20 males and 17 females). A mild
BMD reduction (with lumbar spine Z score lower than -
1.0, but higher than -2.0) was documented in 33 subjects
(40.2% - 17 males, 16 females). A condition of severe
BMD reduction, with a lumbar spine Z score less than -2,
was evident in 12 patients (14.6% - 6 males, 6 females).
Median age was not statistically different in the two
groups: 13 years (range: 5-30) in normal bone density
group, 12 years (range: 5-28) in the group with BMD
reduction (Mann-Whitney test). Table 3 shows the differ-
ent distribution of BMD Z score in prepubertal and puber-
tal subjects. No subject had a history of fractures and
unknown vertebral fractures were excluded by plain chest
X-rays in all of them. The cumulative dosage of inhaled
steroids in the patient group with severe BMD reduction
(BMD <-2) was higher than in the other patients, but the
difference did not reach the statistical significance (p =
0.06). There were no statistically significant differences in
bone density among patients homozygous for ΔF508BMC Pediatrics 2009, 9:61 http://www.biomedcentral.com/1471-2431/9/61
Page 4 of 8
(page number not for citation purposes)
mutation, heterozygous for the same mutation, or carry-
ing different mutations (p: 0.8844). Lumbar spine BMD Z
score was negatively and significantly related to FEV1%
(p: 0.0104 - figure 1). The severity of BMD reduction
seemed to be directly correlated to the clinical severity of
the chronic illness (figures 2 &3): lumbar spine BMD Z
score was positively related to higher Shwachman-Kulczy-
cki score (p: < 0.0001); to further confirm these data lum-
bar spine BMD Z score was also negatively related to
Crispin-Norman score (p: 0.0004).
Analyzing the indicators of nutrition and the body com-
position parameters, we found that BMD Z score was sig-
nificantly reduced in the group of subjects (n = 12) with
BMI SDS <-1 in comparison with the group of subjects
with BMI SDS >-1 (-2.00 ± 1.59 vs -1.04 ± 1.02, p =
0.0076). A positive significant correlation was evident
between lumbar spine BMD Z score and BMI (p: 0.0001).
A similar but not significant positive correlation was
found with BMI-Z score (p: 0.09). The analysis of body
composition parameters showed that lumbar spine BMD
Z score was positively and significantly related both to
total lean mass (p: 0.0047 - figure 4) and to total fat mass
(p: 0.007 - figure 5) expressed in grams. Table 4 shows
clinical characteristics and bone status of the 12 patients
with severe BMD reduction.
Discussion
Several studies have described low bone density in CF
adults, which might represent a potential consistent risk
of fractures [18-21]. Data in pediatric age have been con-
flicting and, until recently, unconvincing. Bhudhikanok et
al [22] reported a significant reduction in total body and
areal BMD for both male and female CF patients.
Gronowitz [23] reported a normal annual increase of
bone mineral density during two years in patients with
CF. More recently, Conway et al [24] showed a low BMD
in 17% of their study population, which was reduced to
9% after correction for body size by BMAD calculation.
None of these studies used an adequate control group of
healthy subjects. However, the Conway group results are
similar to those reported by Kelly et al [25] in a controlled
study evaluating 82 patients (aged 8-18 years) with mild-
moderate CF and pancreatic insufficiency. The Kelly study
showed that BMD deficits in children are largely depend-
ent on the effect of growth and body composition on
bone health, as BMD values normalized after adjustment
for height and lean body mass standard deviation scores.
Conversely, marked differences have been observed by
Bianchi et al in the Milan pediatric CF centre [26]. Longi-
tudinal evaluation over 12-24 months of a sample of 136
young patients (aged 3-24 years) showed that a lumbar
spine Z score less than -1 was present in 66%, independ-
ently of sex, age and correction for body size (BMAD).
Compared to control group, CF patients manifested also a
reduction of fat mass and muscle mass (expressed as fat
free mass). The severity of bone mass reduction was
related to pulmonary function, steroid dose, and the pres-
ence of advanced liver disease with portal hypertension.
Similarly, Buntain et al [27] analyzed bone mass accrual
over 2 years in 85 CF subjects, aged 5-18 years, and
showed that BMD gains over time were significantly less
Table 2: Auxological evaluation and bone status in CF, compared to the control group
CF patients Control subjects p
N° 82 82
Age (mean ± SD) 13.5 ± 5.6 12.9 ± 5.9 0.59
Height Z score -0.42 ± 0.96 -0.46 ± 0.95 0.09
BMI Z score -0.004 ± 1.28 0.11 ± 1.01 0.1
Lumbar spine BMD (Z score ± SD) -1.18 ± 1.16 -0.67 ± 0.92 < 0.0001
Lumbar spine BMAD (mean ± SD) 0.17 ± 0.03 0.19 ± 0.02 0.002
Table 3: Different distribution of BMD Z score in prepubertal and pubertal subjects
Mild BMD reduction Severe BMD reduction Normal BMD
Prepubertal subjects (%) 14 (50%) 3 (10.7%) 11 (39.3%)
Pubertal subjects (%) 19 (35.2%) 9 (16.7%) 26 (48.1%)BMC Pediatrics 2009, 9:61 http://www.biomedcentral.com/1471-2431/9/61
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than in controls and positively associated with total lean
tissue mass. Lung function parameters were significantly
associated with BMD gains during adolescence.
Our study confirms the correlation between BMD, clinical
scores, lung function and body composition seen in liter-
ature [24,26,27]; our results are similar to those of Bianchi
et al [26], but we found a lower percentage of patients
with BMD reduction (54.8% versus 66%). In particular in
our study group, the percentage of patients with severely
reduced BMD was significantly lower (14.6% versus
34%). The difference is probably due to the lower percent-
age of patients with severe lung disease in our study group
(4.8% versus 11.7%) and to the different control group
used, as the healthy subjects were matched for height only
in our study. In contrast with our results, normal BMD
values have been reported in CF patients compared with
healthy height matched subjects [10,28]. Overall, these
discrepancies among studies are probably due to differ-
ences in sample size and composition of the study popu-
lation, and influenced by the severity of lung disease and/
or the presence of CF-related complications, the use of
steroids, comparison with a control group and data cor-
rection for body size.
In our study group anthropometric measures were not
dramatically reduced (mean BMI Z-score: -0.004 ± 1.28;
mean height Z score: -0.42 ± 0.96). The mean FEV1 in our
population was 84.7 ± 20.5% predicted, indicating that
our CF patients had on the whole a relatively mild disease.
Lumbar spine BMD Z score showed a significant positive
correlation with fat and lean mass, confirming that bone
status is strictly related to nutrition. Furthermore, BMD Z
score was significantly reduced in the group of subjects (n
= 12) with BMI SDS <-1 in comparison with the group of
subjects with BMI SDS >-1 (-2.00 ± 1.59 vs -1.04 ± 1.02, p
= 0.0076). Due to the small size of the group of patients
we could not analyze the independent effect of reduced
weight and low lean mass on BMD. In our study, lumbar
spine BMD Z score is significantly reduced in CF patients,
also in prepubertal subjects (see table 3). This finding is
strongly supported by BMAD calculation and the compar-
ison of our population with a height matched control
group. These results contrast with a few studies which sug-
Correlation between lumbar spine Z score and FEV1% Figure 1
Correlation between lumbar spine Z score and 
FEV1%.
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Correlation between lumbar spine Z score and 
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Correlation between lumbar spine Z score and Crispin-Nor- man score Figure 3
Correlation between lumbar spine Z score and 
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Table 4: Clinical characteristics and bone status of the 12 patients with severe BMD reduction.
Patient gender age Height
Z score
BMI
Z score
FEV1% Lumbar spine
BMD
Z score
Lumbar spine BMAD 
(g/cm3)
Additional causes
of BMD reduction
1 female 18 -2.95 -2.30 29 -4.8 0.14 Severe bilial cirrhosis, CFRD
2 male 13 -2.42 -1.22 80.5 -4 0.12 Patient living in a developing country, 
liver disease, CFRD
3 female 15 -1.75 -2.01 93.4 -4 0.12 Late CF diagnosis (14 yrs), celiac 
disease, CFRD
4 male 10 -1.22 1.35 18 -3.9 0.11 Right lung exeresis at age 4
5 female 15 -2.7 0,25 84,8 -3.2 0.13 Short bowel syndrome
6 male 13 -1.1 0,11 99,3 -2,7 0,12 Poor compliance
7 male 13 0.03 -0.48 102,9 -2.5 0.12 Poor compliance
8 female 11 -1.52 1.26 100 -2.3 0.12 Cow milk allergy
9 male 11 -0.24 -0.80 105.2 -2.3 0,12 Low social condition
10 female 9 +0.2 0.84 98 -2.2 0.11 No identified cause
11 female 7 -1.11 -0.26 98.1 -2.1 0. 11 No identified cause
12 male 11 -0.98 -0.89 56.3 -2.1 0.12 Prolonged steroid therapy for ABPA, 
CFRD
CFRD = Cystic Fibrosis Related Diabetes; ABPA = Allergic BronchoPulmonary Aspergillosis
Correlation between lumbar spine Z score and lean mass Figure 4
Correlation between lumbar spine Z score and lean 
mass.
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Correlation between lumbar spine Z score and fat mass Figure 5
Correlation between lumbar spine Z score and fat 
mass.
-6 -5 -4 -3 -2 -1 0 1 2
10000
20000
30000
p: 0.0007
fat mass(g)
Z scoreBMC Pediatrics 2009, 9:61 http://www.biomedcentral.com/1471-2431/9/61
Page 7 of 8
(page number not for citation purposes)
gested that BMD is normal in prepubertal subjects [27]
and that bones are smaller but normally mineralized,
mostly in well nourished children [28-30]. However, we
have to take into consideration the small size of our con-
trol group, caused by the difficulty in identifying appro-
priated control subjects, especially for CF patients with
significant short stature an pubertal delay.
The mean age of our patients with normal BMD is not sta-
tistically different from the age of patients with BMD
reduction, indicating that bone mass reduction can be
present early, during childhood and adolescence, the
bone status being conditioned by nutrition and lung func-
tion in all ages. The cross-sectional structure of our study
did not permit to evaluate, over the years, whether disease
severity progressively affects bone mineral status, as
observed by others [8].
In our study group no subject had a history of fractures or
a detection of unknown vertebral fractures at plain chest
X-rays. These data confirm that the linear correlation, seen
in adults, between the severity of bone demineralization
and the risk of fractures is not evident in pediatric age.
Consequently, it should be possible to improve poor
bone status in CF children and adolescents with an appro-
priate treatment of the disease. In our study no patient
had been treated with oral steroids for more than 15 days
during the previous 2 years; however, all patients used
inhaled corticosteroids. Some authors reported a negative
association between inhaled corticosteroids and bone
mass accrual in children and adolescents with asthma [31]
but such an association is still uncertain in CF patients
[24-26]. We found no significant difference in cumulative
dosage of inhaled steroids comparing patients with severe
BMD reduction (BMD <-2) with those with BMD >-2;
however, we cannot exclude an influence of continued
inhaled steroids on bone mass reduction of our CF
patients.
The work of King et al [11] raised the possibility that
mutations in CFTR gene may be responsible, at least in
part, for low bone density in CF cohorts. The study
reported for the first time a direct link between osteoporo-
sis in CF patients and the presence of ΔF508 mutation. No
association was found in our population, in accordance
with other authors [24,32]; however, our data are not con-
clusive due to the small size of our series.
We did not study the vitamin D serum levels in our pop-
ulation; vitamin D deficiency is common in CF patients
but its role in bone disease is still debatable [24,33,34].
Conclusion
Our results confirm that the degree of CF severity is corre-
lated with an increased risk of low bone mineral density.
A bone mass reduction can be evident early in CF. CF
patients with mild and severe BMD reduction had worse
pulmonary function, body composition and nutritional
status. In CF patients, nutritional evaluation should be
complemented by the analysis of bone status and body
composition by DXA. At this point in our understanding
of CF, maximizing patients' nutritional status, encourag-
ing and maintaining an active lifestyle, and minimizing
the progression of chronic suppurative lung disease are
essential steps to optimize an individual's potential to
attain maximal peak bone mass and thereby reduce the
risk of future fractures.
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